about
Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsTwo decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case reportInterferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon βPosterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis.Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue.Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.Life-threatening asthma attack during prolonged fingolimod treatment: case report.Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects.Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.Natalizumab in spinal multiple sclerosis in a daily clinical setting.Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patientsHydrocephalus during natalizumab treatmentDiffusion-weighted imaging in acute demyelinating myelopathyOcular toxoplasmosis during natalizumab treatmentMotor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practiceFumaric acid esters in psoriasis and multiple sclerosisSevere articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosisAtypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experiencePoor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohortUse of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patientsInfluence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis
P50
Q28286194-5D019A7F-2597-40D0-A985-F0BC6B3A2596Q28601505-1436FD93-8090-4A91-87DF-FA4E08DE2747Q34090086-FB26AA19-CC6F-4814-9260-26D89A3CBCABQ34674636-EC40ABC0-05D9-422C-92FC-B339BC3053E7Q34893972-DD9D9751-FE6B-49B4-8875-9FDA1550021EQ35103997-4405F8FA-3382-43C0-A830-2A97730601C8Q38561380-88A958FF-29F2-4502-ADF0-12BB481C9056Q38954336-74DFD256-9491-44C0-AC68-DC178A7B4FE3Q40022493-37014658-5CA7-468E-9C7A-A131C2BB0FA8Q41611259-AD686D26-BE91-4FB4-B996-FB9BEAF055AFQ42069511-B00DD0BC-EB54-4113-ADA6-8BEEC2482333Q44540131-B3DCC1FE-8FCD-428C-819A-935E7318A72BQ44606110-787470B7-B459-4BF9-A1CD-CDC6F34BDA5CQ47569235-A49A42E1-AB27-4057-8A2F-4F58F8B60869Q47763770-CADF4901-FEB5-4762-B6B9-4BEE4DEE6379Q48247814-475ADD7E-3B3B-4414-9EBF-AC249E723F41Q61943899-F8A2388E-0685-4CB5-B7F6-CC738609D334Q84192373-3E76F700-DBA3-4A1A-AC80-3A20A3C58F89Q84534642-0D24872E-7764-400A-9E57-6443AA56CD5DQ84582881-86530686-4420-4FF7-A3BD-BEEEAEBD8321Q87031517-1C5DFDC9-ED60-4BFE-9291-D6C4E5BA41F6Q87778504-10F8D4EC-E6FA-4956-9BF6-007939546927Q88379867-B53D616C-C5ED-4DD9-A82C-E09E77915B17Q89288955-57E5278E-87A9-420C-96AC-65E6292B054AQ90408706-09DB2EC3-9E45-4F6A-838A-C8A8223C3BAAQ90415027-881DA299-3448-48A6-8649-13BD3295D340Q91834873-B1062A4E-9AC0-401B-886F-5F692E88891FQ92196613-8B86B0A5-6D94-41D0-ACBD-22C0F9456815
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
C Zecca
@ast
C Zecca
@en
C Zecca
@es
C Zecca
@nl
type
label
C Zecca
@ast
C Zecca
@en
C Zecca
@es
C Zecca
@nl
prefLabel
C Zecca
@ast
C Zecca
@en
C Zecca
@es
C Zecca
@nl
P106
P31
P496
0000-0002-9990-3431